Previous close | 26.32 |
Open | 26.25 |
Bid | 26.28 x 3200 |
Ask | 26.19 x 1300 |
Day's range | 26.04 - 26.34 |
52-week range | 25.23 - 40.37 |
Volume | |
Avg. volume | 42,576,651 |
Market cap | 148.755B |
Beta (5Y monthly) | 0.57 |
PE ratio (TTM) | 71.00 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.68 (6.38%) |
Ex-dividend date | 25 Jan 2024 |
1y target est | N/A |
Pfizer stock remains under pressure despite becoming one of the biggest names of the pandemic. Is PFE stock a sell?
While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.